Mark Little, CEO of Spire Biomedical Inc., stated, "We are very excited about the FDA clearance for our coated Decathlon(TM) catheter. Device-related complications are a significant problem in dialysis treatment. Our coated catheter is a new approach to address these issues and significantly differentiates Spire's product offerings in this market segment."
Mr. Little continued, "For over 20 years, Spire has been providing advanced surface treatments for a variety of other medical devices. By combining our dialysis catheter market presence with this proven expertise, we continue to make strides in our pursuit of reducing device-related complications and dysfunction."
ABOUT SPIRE CORPORATION
Spire Corporation is a diversified technology company providing innovative solar energy manufacturing equipment, biomedical devices and optoelectronic components, all based upon a common technology platform. For more information visit www.spirecorp.com.
Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services, as well as other factors described in the Company's Form 10-KSB filed with the Securities and Exchange Commission.
Contact: Spire Corporation Mark Little, 781-275-6000 CEO of Spire Biomedical
Source: Spire Corporation
